Responder group patients with the shunt experience a 50% lower heart failure event rate and a 46% improvement in quality of life over control group TEWKSBURY, MA – August 19, 2024 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the publication in JACC-HF of two-year data from the […]
Two years of echocardiographic data affirm positive effects of atrial shunt therapy on heart structure and function TEWKSBURY, MA – May 7, 2024 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the publication in JAMA Cardiology of two-year echocardiographic data from its REDUCE LAP-HF II randomized clinical trial […]
Second major trial for atrial shunt therapy demonstrates importance of patient selection TEWKSBURY, MA – April 12, 2024 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the recent release of V-Wave’s RELIEVE-HF trial data supporting the evidence base around atrial shunt therapy, which is currently under study in the […]
First-ever phase III randomized controlled trial of atrial shunt therapy shows continued promise TEWKSBURY, MA – May 22, 2023 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced two-year results from its REDUCE LAP-HF II randomized clinical trial confirming safety and sustained efficacy of the Corvia® Atrial Shunt […]
Corvia® Atrial Shunt has the potential to change the way heart failure is treated TEWKSBURY, MA – December 6, 2022 Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), announced the first patient has been randomized in RESPONDER-HF, a global confirmatory trial of the Corvia Atrial Shunt in heart failure […]
Existing investor syndicate supports atrial shunting as effective therapy for heart failure patients TEWKSBURY, MA – JUNE 9, 2022 Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced the closing of a $54 million equity financing from its existing investor syndicate. Funds will be utilized to support a […]
Landmark trial advances understanding of which HFpEF patients may benefit from atrial shunt therapy TEWKSBURY, MA – APRIL 1, 2022 Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), announced publication of analyses from its global, phase III REDUCE LAP-HF II randomized trial of heart failure patients with preserved (HFpEF) […]
REDUCE LAP-HF II study defines treatable HFpEF patient population for atrial shunt therapy TEWKSBURY, MA – FEBRUARY 1, 2022 Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced results from its REDUCE LAP-HF II randomized clinical trial, investigating the safety and efficacy of the Corvia® Atrial Shunt in […]
Large randomized, sham-controlled trial evaluates interatrial shunting in a heart failure population currently without effective treatment TEWKSBURY, MA – November 17, 2020 — Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), today announced completion of randomization in its REDUCE LAP-HF II global, pivotal trial. The trial is evaluating the […]
TEWKSBURY, MA – January 13, 2020— Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced the first Japanese patients were randomized in Toyama and Hyogo under a clinical trial authorization from the Pharmaceutical and Medical Device Agency (PMDA) in the REDUCE LAP-HF II trial. The Corvia InterAtrial […]
